Literature DB >> 12694817

Bcl-2 is significantly overexpressed in localized radio-recurrent prostate carcinoma, compared with localized radio-naive prostate carcinoma.

Charles J Rosser1, Adriana O Reyes, Funda Vakar-Lopez, Lawrence B Levy, Deborah A Kuban, David C Hoover, Andrew K Lee, Louis L Pisters.   

Abstract

PURPOSE: We set out to determine whether patients who underwent prostatectomy for recurrence after external-beam radiotherapy for prostate cancer had a higher incidence of alterations in the apoptotic pathway than did patients who underwent surgery as initial treatment.
MATERIALS AND METHODS: Twenty patients who underwent unsuccessful full-dose external-beam radiotherapy for prostate cancer and subsequently underwent salvage radical surgery (radio-recurrent group), and 20 patients matched for various clinical parameters who underwent only radical prostatectomy for localized or locally advanced prostate cancer (radio-naive group), were studied. Tissue samples were examined for immunoreactivity for p53, p21, Bcl-2, and Ki-67 proteins. Statistically, the two groups were compared using exact logistic regression.
RESULTS: Fifty-five percent of the tumors from patients initially treated with radiotherapy were noted to overexpress Bcl-2; whereas, in the radio-naive group, no patient had Bcl-2 overexpression (p = 0.0004). More patients who underwent salvage radical surgery were found to have a higher mean proliferative index (Ki-67 staining) (39.6%), compared with patients undergoing prostatectomy alone (22.1%), p = 0.0800. No significant difference was noted in immunohistochemical expression of p53 and p21 between the two groups.
CONCLUSIONS: Patients undergoing radical prostatectomy after radiotherapy had a significantly higher rate of Bcl-2 overexpression than did patients who underwent surgery as the initial treatment. Alterations in the apoptotic pathway may be important in the development of local recurrence after radiation therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12694817     DOI: 10.1016/s0360-3016(02)04468-1

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  19 in total

1.  Bcl-2 and bax expression and prostate cancer outcome in men treated with radiotherapy in Radiation Therapy Oncology Group protocol 86-10.

Authors:  Li-Yan Khor; Michelle Desilvio; Rile Li; Timothy J McDonnell; M Elizabeth H Hammond; William T Sause; Miljenko V Pilepich; Paul Okunieff; Howard M Sandler; Alan Pollack
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-07-11       Impact factor: 7.038

2.  Silibinin Preferentially Radiosensitizes Prostate Cancer by Inhibiting DNA Repair Signaling.

Authors:  Dhanya K Nambiar; Paulraj Rajamani; Gagan Deep; Anil K Jain; Rajesh Agarwal; Rana P Singh
Journal:  Mol Cancer Ther       Date:  2015-10-29       Impact factor: 6.261

3.  Antisense Bcl-2 sensitizes prostate cancer cells to radiation.

Authors:  Zhaomei Mu; Paul Hachem; Alan Pollack
Journal:  Prostate       Date:  2005-12-01       Impact factor: 4.104

4.  TCRP1 promotes radioresistance of oral squamous cell carcinoma cells via Akt signal pathway.

Authors:  Yixue Gu; Shasha Fan; Binjie Liu; Guopei Zheng; Yanhui Yu; Yongmei Ouyang; Zhimin He
Journal:  Mol Cell Biochem       Date:  2011-05-21       Impact factor: 3.396

Review 5.  Molecular staging of prostate cancer in the year 2007.

Authors:  Thorsten Schlomm; Andreas Erbersdobler; Martina Mirlacher; Guido Sauter
Journal:  World J Urol       Date:  2007-03-02       Impact factor: 4.226

6.  Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on radiation therapy oncology group protocol 92-02.

Authors:  Li Yan Khor; Jennifer Moughan; Tahseen Al-Saleem; Elizabeth H Hammond; Varagur Venkatesan; Seth A Rosenthal; Mark A Ritter; Howard M Sandler; Gerald E Hanks; William U Shipley; Alan Pollack
Journal:  Clin Cancer Res       Date:  2007-06-15       Impact factor: 12.531

7.  VEGF and Bcl-2 interact via MAPKs signaling pathway in the response to hypoxia in neuroblastoma.

Authors:  Duoduo Wang; Qinjie Weng; Lei Zhang; Qiaojun He; Bo Yang
Journal:  Cell Mol Neurobiol       Date:  2008-12-02       Impact factor: 5.046

8.  Docetaxel and bortezomib downregulate Bcl-2 and sensitize PC-3-Bcl-2 expressing prostate cancer cells to irradiation.

Authors:  Wengang Cao; Kathleen T Shiverick; Kazunori Namiki; Yoshihisa Sakai; Stacy Porvasnik; Cydney Urbanek; Charles J Rosser
Journal:  World J Urol       Date:  2008-07-02       Impact factor: 4.226

9.  Flavonoids activated caspases for apoptosis in human glioblastoma T98G and U87MG cells but not in human normal astrocytes.

Authors:  Arabinda Das; Naren L Banik; Swapan K Ray
Journal:  Cancer       Date:  2010-01-01       Impact factor: 6.860

Review 10.  Molecular fingerprinting of radiation resistant tumors: can we apprehend and rehabilitate the suspects?

Authors:  Charles J Rosser; Micah Gaar; Stacy Porvasnik
Journal:  BMC Cancer       Date:  2009-07-09       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.